Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved survival for advanced wild-type non-small cell lung cancer (NSCLC) significantly, but few studies compared single ICI (SICI)-based treatments and double ICIs (DICI)-based treatments. We summarized the general efficacy of ICI-related treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qian, Zhang, Xue, Huang, Miao, Dai, Xin, Gao, Jing, Li, Song, Sheng, Lei, Huang, Kai, Wang, Jian, Liu, Lian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415225/
https://www.ncbi.nlm.nih.gov/pubmed/34484242
http://dx.doi.org/10.3389/fimmu.2021.731546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415225/
https://www.ncbi.nlm.nih.gov/pubmed/34484242
http://dx.doi.org/10.3389/fimmu.2021.731546

Ejemplares similares